Neuroendocrine Tumor Treatment Industry Growth Expected to Reach $3.6 Billion by 2029 at a CAGR of 10.7% | Segmentation and Growth Opportunities
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Is the Forecast for the Neuroendocrine Tumor Treatment Market Growth in 2025?
The market for neuroendocrine tumor treatment has seen swift expansion in the past few years. Its size is anticipated to increase from $2.17 billion in 2024 to $2.4 billion in 2025, with a compound annual growth rate (CAGR) of 10.6%. The growth observed in the historic period can be credited to factors such as developments in clinical research and understanding, heightened awareness and education, the presence of specialist medical skills, progress in radiation therapy, and enhanced supportive care services.
What Is the Forecast for the Neuroendocrine Tumor Treatment Market Size Through 2029?
The market for neuroendocrine tumor treatment is poised for rapid expansion in the upcoming years, with predictions suggesting it will reach $3.6 billion by 2029, growing at a compound annual growth rate (CAGR) of 10.7%. Factors driving this growth during the forecast period include advancements in precision medicine, developments in immunotherapy, minimally invasive surgery techniques, increasing incidence rates, and the advent of telemedicine and remote care. Trends anticipated in this period include progress in diagnostic technologies, improvements in peptide receptor radionuclide therapy (PRRT), the application of nanotechnology in drug delivery, the emergence of radiopharmaceuticals, and cross-disciplinary cooperation.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12248&type=smp
What are the Key Market Players in Neuroendocrine Tumor Treatment Market and How They’re Evolving?
Major companies operating in the neuroendocrine tumor treatment market include Pfizer Inc., F Hoffmann-La Roche AG, Abbvie Inc., Novartis AG, Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca, Takeda Pharmaceutical, Eli Lilly And Company, Amgen Inc., Merck & Co. Inc., Boehringer Ingelheim International GmbH, Servier, Teva Pharmaceutical Industries Ltd., Ipsen Pharma SAS, Exelixis Inc., Advanced Accelerator Applications SA, Hutchison Medipharma Ltd., Tarveda Therapeutics, GlycoMira Therapeutics Inc, AVEO Pharmaceuticals Inc., Progenics Pharmaceuticals Inc., Callisto Pharmaceuticals Pvt Ltd., Chiasma Inc.
What Are the Primary Growth Drivers in the Neuroendocrine Tumor Treatment Market?
The increasing occurrence of neuroendocrine tumors is anticipated to drive the expansion of the neuroendocrine tumor treatment market. Neuroendocrine tumors (NETs) are a rare form of tumors that originate from neuroendocrine cells. The treatment of these tumors is crucial for their cure and works to manage symptoms, control the development of the tumor, and uses radiation therapy to eliminate tumor cells. As per the data provided by the American Society of Clinical Oncology (ASCO), a professional organization based in the US, in March 2023, over 12,000 Americans are diagnosed with these tumors annually, with an estimated 171,000 individuals living with this diagnosis in 2023. Moreover, Cancer Australia, an Australian cancer control organization, reported in August 2022 that 5,437 Australians were diagnosed with neuroendocrine tumors in 2022, amounting to 3.4% of all new cases diagnosed that year. Thus, the rising occurrence of neuroendocrine tumors is fueling the growth of the neuroendocrine tumor treatment market.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=12248&type=smp
What Are the Leading Segments in the Global Neuroendocrine Tumor Treatment Industry?
The neuroendocrine tumor treatment market covered in this report is segmented –
1) By Product: Somatostatin Analogs (SSAs), Targeted Therapy, Chemotherapy, Others Products
2) By Indication: Lungs, Pancreas, Gastrointestinal, Others Indications
3) By End-Users: Hospitals, Oncology Centers, Other End-Users
Subsegments:
1) By Somatostatin Analogs (SSAs): Octreotide, Lanreotide
2) By Targeted Therapy: Tyrosine Kinase Inhibitors (TKIs), Peptide Receptor Radionuclide Therapy (PRRT)
3) By Chemotherapy: Traditional Chemotherapy Agents, Combination Chemotherapy Regimens
4) By Other Products: Immunotherapy, Supportive Care Medications
What Are the Key Market Trends in the Neuroendocrine Tumor Treatment Industry?
The growing trend of using clinical drug development for treatment in the neuroendocrine tumor treatment market is being leveraged by major players in the field. To maintain their market position, these companies are working on groundbreaking therapies. For example, Viewpoint Molecular Targeting, Inc., an American pharmaceutical corporation, announced in October 2022 that it received a fast-track designation from the U.S. Food and Drug Administration (FDA) for the development of [212Pb] VMT-a-NET. This drug is used to treat patients suffering from SSTR2-positive unresectable or metastatic neuroendocrine tumors (NETs) and is a targeted alpha-particle therapy (TAT) specifically designed to eliminate cancer cells expressing somatostatin receptors specifically. The FDA’s fast-track designation is meant to speed up both the development and review process of [212Pb] VMT-a-NET for NET treatments. The designation is exclusively given to drugs that could potentially significantly increase the safety or efficacy of treatment for serious illnesses.
Access The Full Report Here:
What Is the Regional Outlook for the Neuroendocrine Tumor Treatment Market?
North America was the largest region in the neuroendocrine tumor treatment market in 2024. The regions covered in the neuroendocrine tumor treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Purchase The Full Report Today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12248
This Report Delivers Insight On:
1. How big is the neuroendocrine tumor treatment market, and how is it changing globally?
2. Who are the major companies in the neuroendocrine tumor treatment market, and how are they performing?
3. What are the key opportunities and risks in the neuroendocrine tumor treatment market right now?
4. Which products or customer segments are growing the most in the neuroendocrine tumor treatment market?
5. What factors are helping or slowing down the growth of the neuroendocrine tumor treatment market?
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
